Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, localized prostate cancer, which achieved its primary endpoint, supported by secondary endpoints Poster presentation: Daniel Sterman M.D., Professor at NYU Langone Health will present ‘Multi-omics analysis of CAN-2409 in non-small cell lung cancer (NSCLC) identifie ...